ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic

Accelerating COVID-19 Treatment Interventions and Vaccines (ACTIV) was initiated by the US government to rapidly develop and test vaccines and therapeutics against COVID-19 in 2020. The ACTIV Therapeutics-Clinical Working Group selected ACTIV trial teams and clinical networks to expeditiously develop and launch master protocols based on therapeutic targets and patient populations. The suite of clinical trials was designed to collectively inform therapeutic care for COVID-19 outpatient, inpatient, and intensive care populations globally. In this report, we highlight challenges, strategies, and solutions around clinical protocol development and regulatory approval to document our experience and propose plans for future similar healthcare emergencies.

Authors

Institutions

Publication Details

Journal
UNC Libraries
Published
2024-11-05
DOI
https://doi.org/10.17615/wtgx-4h88
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic

William A. Fischer, Christopher John Lindsell, Christina E. Barkauskas, Stacey J. Adam et al.
UNC Libraries
Health Systems, Economic Evaluations, Quality of Life
article

ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic

William A. Fischer, Christopher John Lindsell, Christina E. Barkauskas, Stacey J. Adam, Ithan D. Peltan, Mahesh Parmar, Matthew S. Shotwell, Michael A. Proschan, Lisa M. LaVange, Prasanna Jagannathan, Maryam Keshtkar‐Jahromi, Seema Nayak, Kevin W. Gibbs, David M. Vock, Kevin J. Anstrom, Elizabeth S. Higgs, Samuel Morris Brown, Tammy Yokum, Eric S. Daar, Roger Paredes, Michael D. Hughes
article en

Abstract

Accelerating COVID-19 Treatment Interventions and Vaccines (ACTIV) was initiated by the US government to rapidly develop and test vaccines and therapeutics against COVID-19 in 2020. The ACTIV Therapeutics-Clinical Working Group selected ACTIV trial teams and clinical networks to expeditiously develop and launch master protocols based on therapeutic targets and patient populations. The suite of clinical trials was designed to collectively inform therapeutic care for COVID-19 outpatient, inpatient, and intensive care populations globally. In this report, we highlight challenges, strategies, and solutions around clinical protocol development and regulatory approval to document our experience and propose plans for future similar healthcare emergencies.

UNC Libraries
University of North Carolina at Chapel Hill (US)
Foundation for the National Institutes of Health, National Institutes of Health
Good health and well-being
Openalex Percentile: Top 76%
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.